~~<i id='D667A8E634'><strike id='D667A8E634'><tt id='D667A8E634'><pre id='D667A8E634'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：Wikipedia 2025-09-29 03:46:06 Page View：3488

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： TytoCare raises $49 million to build out AI
Next article： Medical records are filled with copy

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Patients, digital health players weigh in on FTC's data privacy plan

AdobeThisyearhasseentheFederalTradeCommissioncrackdownondigitalhealthcompanies’irresponsibledatause.

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

ProMED, early warning system on disease outbreaks, in peril

ProMEDmapScreengrabviaProMEDTheearlywarningdiseasenetworkthatalertedtheworldtotheoriginalSARSoutbrea